GlassScriptPhysician profile
Saira Jamal
NPI 1760496004
$2,340.75
in general payments reported to CMS, 2019-2025
32 companies · $538 in 2025
The $538 reported for 2025 was more than what 82% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $275 · 2021: $273 · 2022: $354 · 2023: $380 · 2024: $249 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $282.55 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $276.19 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $153.98 | 2021-2025 | |
| Stryker Corporation | $140.82 | 2022 | |
| Medicure Pharma INC. | $128.05 | 2020-2021 | |
| Pfizer INC. | $125.62 | 2019-2023 | |
| Lundbeck LLC | $111.39 | 2023-2025 | Rexulti, Vyepti |
| Biogen, INC. | $109.06 | 2020-2022 | |
| Lilly USA, LLC | $107.77 | 2022-2025 | Zepbound, Jardiance, Kisunla |
| Eisai INC. | $105.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $93.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $66.90 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $55.56 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $55.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.23 | 2023-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $42.89 | 2022-2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $37.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.76 | 2019-2022 | |
| Corcept Therapeutics | $34.63 | 2025 | Korlym |
| Exact Sciences Corporation | $30.55 | 2023-2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $27.82 | 2023-2024 | Contrave |
| Inspire Medical Systems, INC. | $26.91 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.37 | 2023 | Jardiance |
| Axsome Therapeutics, INC. | $20.96 | 2025 | Auvelity |
| Ibsa Pharma INC. | $20.05 | 2025 | Tirosint, Licart, Flector |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.57 | 2023 | |
| Dynavax Technologies Corporation | $16.22 | 2025 | Heplisav-B |
| Merz North America, INC. | $15.83 | 2019 | |
| Abbott Laboratories | $15.39 | 2025 | Proclaim |
| Sumitomo Pharma America, INC. | $14.87 | 2025 | Gemtesa |
| Allergan, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.